SAT0322 PREVALENCE AND RISK FACTORS FOR LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN SYSTEMIC SCLEROSIS: RESULTS FROM RESCLE REGISTRY
Authors: A. González, J. L. Patier, M. López-Rodríguez, A. Guillén del Castillo, M. Rubio-Rivas, A. Argibay, B. Marí-Alfonso, A. J. Chamorro, A. B. Madroñero-Vuelta, E. L. Callejas-Moraga, C. González-Echávarri, N. Ortego, V. Fonollosa-Pla, C. P. Simeón-Aznar, O. B. O. R. I. Autoimmune Diseases Study Group (Geas)
Journal: Annals of the Rheumatic Diseases (2020)

Background: Left ventricular diastolic dysfunction (LVDD) is a very common finding in heart involvement in Systemic Sclerosis (SSc). Objectives: To determine the prevalence, risk factors and mortality associated with LVDD in a cohort of patients with SSc. Methods: A retrospective study was conducted with data from the multicentre Spanish Scleroderma Registry (RESCLE). A case-control study was performed to identify factors associated with LVDD. Results: Out of 1517 cases of SSc, 319 (21%) developed LVDD. Basal characteristics are shown in Table 1. In multivariate analysis, LVDD was associated to older age at diagnosis of SSc [54 vs 44 years, OR 1.05 (1,04-1.06)], presence of telangiectasia [67 vs 59%, OR 1.42 (1,88-1.08)], and treatment with calcium channel blockers [50 vs. 45%, OR 1.55 (1.16-1.96)], and inversely correlated to treatment with ACE inhibitors [74 vs. 83%, OR 0.59 (0.44-0.8)]. Mortality was increased in patients with LVDD (24 vs 17%, OR 1.4, p = 0.01). Kaplan–Meier cumulative survival for the SSc cohort, according to the presence or absence of LVDD showed significant differences in 30 years from the first SSc symptom (59 vs. 70%, p = 0.04). Table 1. Number of patients 1517 319 (21% ) 1198 (79% ) P Limited SSc 923 (61%) 201 (63%) 722 (60%) 0.438 Diffuse SSc 304 (20%) 51 (16%) 253 (21%) 0.041 Sine Sclerodema SSc 174 (11%) 47 (15%) 127 (11%) 0.048 Age at disease onset (years ) med±SD 46.4±16.5 54.1±15.9 44.5±16.1 &lt;0.001 Arterial hypertensión 491 (33%) 148 (48%) 343 (30%) &lt;0.001 Digital ulcers 615 (41%) 108 (34%) 507 (42%) 0.006 Telangiectasia 918 (61%) 212 (67%) 706 (59%) 0.011 Interstitial lung disease 645 (43%) 153 (48%) 492 (41%) 0.021 Pulmonary hypertension 139 (9.2%) 34 (11%) 105 (8.8%) 0.325 Capillaroscopy Slow pattern 673 (51%) 130 (46%) 543 (53%) 0.038 Centromere Antibodies 679 (49%) 154 (55%) 525 (48%) 0.032 Conclusion: In our cohort, LVDD is relative common in SSc patients, and it is associated with older age at diagnosis, treatment with calcium channel blockers and telangiectasia. ACE inhibitors could play a protective role against the development of LVDD. Mortality is higher in SSc patients with LVDD, and is more significative over time. References: [1]Tennøe AH et al . Left Ventricular Diastolic Dysfunction Predicts Mortality in Patients with Systemic Sclerosis. J Am Coll Cardiol. 2018;72:1804-13 Disclosure of Interests: Andrés González: None declared, Jose Luis Patier: None declared, Mónica López-Rodríguez: None declared, Alfredo Guillén del Castillo: None declared, Manuel Rubio-Rivas: None declared, Ana Argibay: None declared, Begoña Marí-Alfonso: None declared, Antonio-J Chamorro: None declared, Ana Belén Madroñero-Vuelta: None declared, Eduardo L. Callejas-Moraga: None declared, Cristina González-Echávarri: None declared, Norberto Ortego: None declared, Vicent Fonollosa-Pla Consultant of: Actelion pharmaceuticals, GSK, MSD., Carmen Pilar Simeón-Aznar Consultant of: Actelion pharmaceuticals, GSK, MSD., on behalf of RESCLE Investigators, Autoimmune Diseases Study Group (GEAS): None declared